William Pao

66.6k citations

230 papers · 35.5k indexed · 20 hit papers · h-index 86

Impact in

Oncology top 0.01%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 175
- Lung Cancer Treatments and Mutations 165
- Lung Cancer Diagnosis and Treatment 33
Oncology 121
- Colorectal Cancer Treatments and Studies 42
- Lung Cancer Research Studies 41
- HER2/EGFR in Cancer Research 37

Co-authors: Vincent A. Miller Mark G. Kris Gregory J. Riely Maureen F. Zakowski Marc Ladanyi Katerina Politi Harold Varmus Juliann Chmielecki
Journals: Journal of Clinical Oncology (53 papers)Clinical Cancer Research (32 papers)Journal of Thoracic Oncology (16 papers)Cancer Research (8 papers)PLoS ONE (7 papers)
Partner nations: United States China Germany

In The Last Decade

William Pao

227 papers receiving 34.7k citations

Hit Papers

15 papers align trajectories log scale

Acquired resistance to TKIs in solid tumours: learning from lung cancer 2014 · 677 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Nature Reviews Clinical Oncology
2014 Nature Medicine
2013 Clinical Cancer Research
2013 Journal of Clinical Oncology
2012 Cancer Discovery
2011 The Lancet Oncology
2011 Clinical Cancer Research
2010 Nature reviews. Cancer
2010 Clinical Cancer Research
2009 Journal of Clinical Oncology
2009 Journal of Clinical Oncology
2007 Journal of Clinical Investigation
2006 Clinical Cancer Research
2006 Clinical Cancer Research
2005 PLoS Medicine
2005 Journal of Clinical Oncology
2005 PLoS Medicine
2004 Proceedings of the National Academy of Sciences
2004 Journal of Clinical Oncology
1995 Nature

Peers

Countries citing papers authored by William Pao

Since Specialization

Citations

This map shows the geographic impact of William Pao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Pao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Pao more than expected).

Fields of papers citing papers by William Pao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Pao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Pao. The network helps show where William Pao may publish in the future.

Co-authors

The 25 scholars most cited alongside William Pao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William Pao Line = papers co-authored together William Pao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer Cancer Research ·Eiki Ichihara, David Westover, Catherine B. Meador, Yingjun Yan, Joshua A. Bauer, Lu Wang, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren A.E. Cross, William Pao, Christine M. Lovly	2017	104
2	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer Cancer Research ·Katherine Amato, Shan Wang, Li Tan, Andrew K. Hastings, Wenqiang Song, Christine M. Lovly, Catherine B. Meador, Fei Ye, Lu Wang, Justin M. Balko, Daniel C. Colvin, Justin Cates, William Pao, Nathanael S. Gray, Jin Chen	2016	84
3	A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Molecular Cancer Therapeutics ·Junfeng Xia, Peilin Jia, Katherine E. Hutchinson, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, William Pao, Zhongming Zhao	2014	65
4	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes Cancer Discovery ·Juliann Chmielecki, Katherine E. Hutchinson, Garrett M. Frampton, Zachary R. Chalmers, Adrienne Johnson, Chanjuan Shi, Julia A. Elvin, Siraj M. Ali, Jeffrey S. Ross, Olca Baştürk, Sohail Balasubramanian, Doron Lipson, Roman Yelensky, William Pao, Vincent A. Miller, David S. Klimstra, Philip J. Stephens	2014	126
5	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations Cancer Discovery ·Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao	2014	295
6	FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer Clinical Cancer Research ·Rui Wang, Lei Wang, Yuan Li, Haichuan Hu, Lei Shen, Xuxia Shen, Yunjian Pan, Ting Ye, Yang Zhang, Xiaoyang Luo, Yiliang Zhang, Bin Pan, Bin Li, Hang Li, Jie Zhang, William Pao, Hongbin Ji, Yihua Sun, Haiquan Chen	2014	116
7	Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer Molecular Cancer Therapeutics ·Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Caroline A. Nebhan, Valentina Pirazzoli, Lu Wang, Huy Gia Vuong, Katherine E. Hutchinson, Peilin Jia, Xi Chen, Rosana Eisenberg, Marc Ladanyi, Katerina Politi, Zhongming Zhao, Christine M. Lovly, Darren A.E. Cross, William Pao	2014	22
8	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants Clinical Cancer Research ·Johannes M. Heuckmann, Hyatt Balke‐Want, Florian Malchers, Martin Peifer, Martin L. Sos, Mirjam Koker, Lydia Meder, Christine M. Lovly, Lukas C. Heukamp, William Pao, Ralf Küppers, Roman K. Thomas	2012	201
9	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proceedings of the National Academy of Sciences ·Joan T. Garrett, Maria G. Olivares, Cammie Rinehart, Nara De Matos Granja-Ingram, Violeta Sánchez, Anindita Chakrabarty, Bhuvanesh Dave, Rebecca S. Cook, William Pao, Eliot McKinely, H. Charles Manning, Jenny C. Chang, Carlos L. Arteaga	2011	359
10	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors Clinical Cancer Research ·Johannes M. Heuckmann, Michael Hölzel, Martin L. Sos, Stefanie Heynck, Hyatt Balke‐Want, Mirjam Koker, Martin Peifer, Jonathan M. Weiss, Christine M. Lovly, Christian Grütter, Daniel Rauh, William Pao, Roman K. Thomas	2011	147
11	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib Clinical Cancer Research ·Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller	2011	50
12	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Clinical Cancer Research ·Maria E. Arcila, Geoffrey R. Oxnard, Khédoudja Nafa, Gregory J. Riely, Stephen B. Solomon, Maureen F. Zakowski, Mark G. Kris, William Pao, Vincent A. Miller, Marc Ladanyi Hit paper breakdown →	2011	476
13	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development Clinical Cancer Research ·Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie W. Rusch, Marc Ladanyi, Naiyer A. Rizvi, Lawrence H. Schwartz	2010	82
14	Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer Clinical Cancer Research ·Juliann Chmielecki, William Pao	2010	4
15	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report Clinical Cancer Research ·Nicolas Girard, Emil Lou, Christopher G. Azzoli, Rekha Reddy, Mark E. Robson, Megan Harlan, Irene Orlow, Yasushi Yatabe, Khédoudja Nafa, Marc Ladanyi, Agnès Viale, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, Robert J. Klein, Keitaro Matsuo, William Pao	2010	70
16	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Milton, Luke T. Nordquist, David G. Pfister, Steven Piantadosi, Joan H. Schiller, R. Smith, Thomas J. Smith, John R. Strawn, David Trent, Giuseppe Giaccone Hit paper breakdown →	2009	752
17	Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications Clinical Cancer Research ·Charles M. Rudin, Érika Ávila-Tang, Curtis C. Harris, James G. Herman, Fred R. Hirsch, William Pao, Ann G. Schwartz, Kirsi Vähäkangas, Jonathan M. Samet	2009	123
18	Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas Clinical Cancer Research ·Nicolas Girard, Ronglai Shen, Tianhua Guo, Maureen F. Zakowski, Adriana Heguy, Gregory J. Riely, James Huang, Christopher Lau, Alex Lash, Marc Ladanyi, Agnès Viale, Cristina R. Antonescu, William D. Travis, Valerie W. Rusch, Mark G. Kris, William Pao	2009	147
19	Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer Cancer Research ·Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman, Barry S. Taylor, William Pao, Shinichi Toyooka, Marc Ladanyi, Adi F. Gazdar, Neal Rosen, David B. Solit	2008	195
20	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Clinical Cancer Research ·Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao Hit paper breakdown →	2006	664

About William Pao

William Pao is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Microbiology and Molecular Biology, having authored 230 papers that have together received 35.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (165 papers), Cancer Genomics and Diagnostics (62 papers), Colorectal Cancer Treatments and Studies (42 papers), Lung Cancer Research Studies (41 papers), HER2/EGFR in Cancer Research (37 papers), Lung Cancer Diagnosis and Treatment (33 papers), Cancer therapeutics and mechanisms (20 papers) and RNA modifications and cancer (17 papers). The work is most often cited by research in Oncology (21.0k citations), Pulmonary and Respiratory Medicine (24.1k citations), Cancer Research (8.0k citations), Molecular Biology (14.2k citations) and Pathology and Forensic Medicine (2.5k citations). William Pao has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Vincent A. Miller, Mark G. Kris, Gregory J. Riely, Maureen F. Zakowski, Marc Ladanyi, Katerina Politi, Harold Varmus, Juliann Chmielecki, Nicolas Girard and Robert T. Heelan. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Cancer Research and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact